Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15844016 | 0.89 | TACR1 (0.58) | TACR1CACNA1HBACE1BACE2MTOR | |
| SCHEMBL20088441 | 0.89 | TACR1 (0.50) | TACR1BACE1BACE2MTORMLYCD | |
| SCHEMBL1274028 | 0.84 | TACR1 (0.50) | TACR1CACNA1HBACE1BACE2MTOR | |
| SCHEMBL20088445 | 0.83 | TACR1 (0.47) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL25780517 | 0.82 | MTOR (0.46) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL10296153 | 0.80 | LMNA (0.45) | CARM1AOC3ALDH1A1 | |
| SCHEMBL21565748 | 0.79 | TACR1 (0.53) | TACR1MTORMLYCD | |
| Trifluoroacetic Acid SCHEMBL1273967 | 0.79 | TACR1 (0.49) | TACR1CACNA1HBACE1BACE2MTOR | |
| SCHEMBL20088443 | 0.79 | CYP3A4 (0.48) | TACR1MTORMLYCD | |
| SCHEMBL13884195 | 0.78 | L3MBTL1 (0.64) | BACE1MLYCDAOC3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | TACR1 1462/4885CACNA1H 65/4885BACE1 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.